What We Do

  With Cutting-edge Technologies  

Harnessing the power of patients' immune systems by eliciting natural immune responses, addressing needs based on unique profile, and helping hundreds of millions.

Contact us

Jinwei Hightlights



Shanghai Jinwei Biotechnology Co., Ltd. (Jinwei) is a biotechnology company dedicated to pursue innovative technology to develop cures for people with serious and life-threatening diseases.

Jinwei has obtained exclusive licenses of multiple patents and other intellectual property owned by the Pasteur Institute and Theravectys for development, manufacture and commercialization of therapeutic products based on lentiviral vectors.

We offer lentiviral vector development, manufacturing and analytical testing for clinical and commercial supply. Our services include Process and Analytical Methods Development, Full GMP Production, with USP and DSP, Fill & Finish, Quality Control & Quality Assurance and Regulatory Support. 

The GMP production facility located in Shanghai is dedicated to provide safe and reliable viral vector-based products and CMO/CDMO services, helping to translate early stage research into commercially viable therapies.

In addition, Jinwei has established partnership with the Huashan Hospital to develop leading edge therapies for various cancers such as liver and prostate cancersas well as infectious diseases such as HBV and Tuberculosis.


  Lentiviral Vector  

Our innovative lentiviral vectors enable dendritic cells to train immune cells to destroy infected cells or cancer cells. Our lentiviral vectors can efficiently transduce dendritic cells and thus elicit a protective cellular immune response. Antigens are presented in a sustained manner through the endogenous pathway. This leads to the activation and maturation of key immune effectors with unprecedented efficacy.


  Latest Update